- Stock: In Stock
- Brand: Incepta Pharmaceuticals
- Product ID: Eltrombopag Olamine
100% Secure Payment
Eltropag 25 Tablet
Description
Eltrombopag is an orally bioavailable, small-molecule TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor and initiates signaling cascades that induce proliferation and differentiation from bone marrow progenitor cells.
Indications
Eltrombopag is indicated for: Thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune. (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Thrombocytopenia in patients with chronic hepatitis-C to allow the initiation and maintenance of interferon-based therapy. Patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.
Dosage & Administration
Take on an empty stomach (1 hour before or 2 hours after a meal).Chronic ITP: Initial dose of Eltrombopag for most of the adult and pediatric patients of 6 years. & older is 50 mg once daily. For pediatric patients aged from 1 to 5 years the initial dose. should be 25 mg once daily. Adjust to maintain platelet count greater than or equal to 50 x 109/L.
Do not exceed 75 mg per day. Chronic Hepatitis C-associated Thrombocytopenia: Initiate Eltrombopag at 25 mg once daily for all patients. Adjust to achieve target platelet count required to initiate antiviral therapy. Do not exceed a daily dose of 100 mg. Severe Aplastic Anemia: Initiate Eltrombopag at 50 mg once daily for most patients. Adjust to maintain platelet count greater than or equal to 50 x 109/L. Do not exceed 150 mg per day.
Side Effects
In adult patients with ITP, the most common adverse reactions were: Nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection etc.The most common adverse drug reactions seen in children of 1 year and older is upper respiratory tract infections and nasopharyngitis. Patients with chronic hepatitis C associated thrombocytopenia: Anemia, pyrexia, fatigue, headache, nausea, diarrhea, alopecia and peripheral edema is very common. Patents with severe aplastic anemia: The most common adverse effect is nausea, fatigue, cough, diarrhea, headache etc.
Precautions
Hepatotoxicity: In this case, monitor liver function before and during therapy. Thromboembolic complication: Portal vein thrombosis has been reported in patients with chronic liver disease receiving Eltrombopag, so platelet count should be measured carefully.
Use in Pregnancy & Lactation
Pregnancy: Pregnancy Category C. Nursing mothers: It is not known whether eltrombopag is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue eltrombopag taking into account the importance of eltrombopag to the mother.
Drug Interaction
Eltrombopag interacts with polyvalent cation-containing Antacids. .Caution should be taken when administered with OATP1B1 substrate and BCRP substrate (Rosuvastatin), Protease inhibitors (Iopinavir) etc.
Over Dose
In case of an overdose, consider oral administration of a metal cation-containing preparation, such as calcium, aluminum, or magnesium preparations to chelate eltrombopag and thus limit absorption. Closely monitor platelet counts.
Storage
Store in a cool and dry place. Keep away from light and moisture and out of reach of children.
